Cancers | Feature Papers from the Second Half of 2024 in the Section “Cancer Drug Development”

As all the articles published in Cancers (ISSN: 2072-6694) are open access, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the second half of 2024 in the Section “Cancer Drug Development”, which are listed below.

1. “Anticancer Effect of PtIIPHENSS, PtII5MESS, PtII56MESS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer”
by Maria George Elias, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott and Janice R. Aldrich-Wright
Cancers 2024, 16(14), 2544; https://doi.org/10.3390/cancers16142544
Available online: https://www.mdpi.com/2072-6694/16/14/2544

2. “A New Vista of Aldehyde Dehydrogenase 1A3 (ALDH1A3): New Specific Inhibitors and Activity-Based Probes Targeting ALDH1A3 Dependent Pathways in Glioblastoma, Mesothelioma and Other Cancers”
by Lorenzo Magrassi, Giulia Pinton, Sabino Luzzi, Sergio Comincini, Andrea Scravaglieri, Valentina Gigliotti, Bianca Laura Bernardoni, Ilaria D’Agostino, Francesca Juretich, Concettina La Motta et al.
Cancers 2024, 16(13), 2397; https://doi.org/10.3390/cancers16132397
Available online: https://www.mdpi.com/2072-6694/16/13/2397

3. “Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer”
by Sho Sato, Tadahiro Shoji, Ami Jo, Haruka Otsuka, Marina Abe, Shunsuke Tatsuki, Yohei Chiba, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa et al.
Cancers 2024, 16(14), 2545; https://doi.org/10.3390/cancers16142545
Available online: https://www.mdpi.com/2072-6694/16/14/2545

4. “Dose Optimization of Targeted Therapies for Oncologic Indications”
by Marjorie E. Zettler
Cancers 2024, 16(12), 2180; https://doi.org/10.3390/cancers16122180
Available online: https://www.mdpi.com/2072-6694/16/12/2180

5. “The Anticancer Application of Delivery Systems for Honokiol and Magnolol”
by Katarzyna Dominiak, Aleksandra Gostyńska, Michał Szulc and Maciej Stawny
Cancers 2024, 16(12), 2257; https://doi.org/10.3390/cancers16122257
Available online: https://www.mdpi.com/2072-6694/16/12/2257

6. “Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment”
by Taufeeque Ali, Daniel Li, Thilini Nimasha Fernando Ponnamperumage, Alexis Kimberly Peterson, Jatin Pandey, Kulsum Fatima, John Brzezinski, Julia Anna Rose Jakusz, Hanlun Gao, Gilbert Edward Koelsch et al.
Cancers 2024, 16(12), 2171; https://doi.org/10.3390/cancers16122171
Available online: https://www.mdpi.com/2072-6694/16/12/2171

7. “Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives”
by Francesca Carosi, Elisabetta Broseghini, Laura Fabbri, Giacomo Corradi, Riccardo Gili, Valentina Forte, Roberta Roncarati, Daria Maria Filippini and Manuela Ferracin
Cancers 2024, 16(15), 2752; https://doi.org/10.3390/cancers16152752
Available online: https://www.mdpi.com/2072-6694/16/15/2752

8. “Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development”
by Whi-An Kwon, Seo-Yeon Lee, Tae Yoong Jeong, Hyeon Hoe Kim and Min-Kyung Lee
Cancers 2024, 16(13), 2420; https://doi.org/10.3390/cancers16132420
Available online: https://www.mdpi.com/2072-6694/16/13/2420

9. “Mechanisms of the Antineoplastic Effects of New Fluoroquinolones in 2D and 3D Human Breast and Bladder Cancer Cell Lines”
by Nicole Ferrario, Emanuela Marras, Veronica Vivona, Federica Randisi, Antonino Nicolò Fallica, Agostino Marrazzo, Gianpaolo Perletti and Marzia Bruna Gariboldi
Cancers 2024, 16(12), 2227; https://doi.org/10.3390/cancers16122227
Available online: https://www.mdpi.com/2072-6694/16/12/2227

10. “Perioperative Immunosuppressive Factors during Cancer Surgery: An Updated Review”
by Lucillia Bezu, Dilara Akçal Öksüz, Max Bell, Donal Buggy, Oscar Diaz-Cambronero, Mats Enlund, Patrice Forget, Anil Gupta, Markus W. Hollmann, Daniela Ionescu et al.
Cancers 2024, 16(13), 2304; https://doi.org/10.3390/cancers16132304
Available online: https://www.mdpi.com/2072-6694/16/13/2304

11. “Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development”
by Kyaw Z. Thein, Yin M. Myat, Byung S. Park, Kalpana Panigrahi and Shivaani Kummar
Cancers 2024, 16(14), 2529; https://doi.org/10.3390/cancers16142529
Available online: https://www.mdpi.com/2072-6694/16/14/2529

12. “Overcoming Chemoresistance in Cancer: The Promise of Crizotinib”
by Sanaa Musa, Noor Amara, Adan Selawi, Junbiao Wang, Cristina Marchini, Abed Agbarya and Jamal Mahajna
Cancers 2024, 16(13), 2479; https://doi.org/10.3390/cancers16132479
Available online: https://www.mdpi.com/2072-6694/16/13/2479

13. “Molecular Interactions of the Plant Steroid Hormone Epibrassinolide on Human Drug-Sensitive and Drug-Resistant Small-Cell Lung Carcinoma Cells”
by David Sadava and Shiuan Chen
Cancers 2024, 16(22), 3812; https://doi.org/10.3390/cancers16223812
Available online: https://www.mdpi.com/2072-6694/16/22/3812

14. “Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies”
by Christiana Mo, Michelle Sterpi, Hyein Jeon and Fernand Bteich
Cancers 2024, 16(16), 2854; https://doi.org/10.3390/cancers16162854
Available online: https://www.mdpi.com/2072-6694/16/16/2854

15. “Genotoxic and Anti-Migratory Effects of Camptothecin Combined with Celastrol or Resveratrol in Metastatic and Stem-like Cells of Colon Cancer”
by Helena Moreira, Anna Szyjka, Dorota Bęben, Oliwia Siwiela, Anna Radajewska, Nadia Stankiewicz, Małgorzata Grzesiak, Benita Wiatrak, Fathi Emhemmed, Christian D. Muller et al.
Cancers 2024, 16(19), 3279; https://doi.org/10.3390/cancers16193279
Available online: https://www.mdpi.com/2072-6694/16/19/3279

You are invited to view and submit relevant papers to the journal Cancers.

Cancers Editorial Office